Elekta (OTCMKTS:EKTAY) Stock Jumps 5.5% – Still a Buy?

Elekta AB (OTCMKTS:EKTAY) shot up 5.5% during mid-day trading on Monday. The company traded as high as $5.57 and last traded at $5.57. Approximately 100 shares changed hands during trading, a decline of 97% from the average daily volume of 2,869 shares. The stock had previously closed at $5.28.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat, Elekta presently has a consensus rating of “Hold”.

Elekta Stock Up 3.0%

The company has a market cap of $2.05 billion, a PE ratio of -46.41 and a beta of 1.03. The business has a 50-day simple moving average of $5.38 and a 200-day simple moving average of $5.49. The company has a quick ratio of 0.62, a current ratio of 0.86 and a debt-to-equity ratio of 0.45.

Elekta (OTCMKTS:EKTAY) last issued its quarterly earnings data on Thursday, August 27th. The company reported $0.07 EPS for the quarter. The company had revenue of $372.30 million for the quarter. Elekta had a positive return on equity of 13.47% and a negative net margin of 2.38%. Equities research analysts anticipate that Elekta AB will post 0.43 EPS for the current year.

Elekta Company Profile

Elekta AB is a Sweden-based medical technology company that develops and supplies equipment, software and related services for radiation oncology and neurosurgery. Its technologies are used by hospitals and cancer treatment centers to plan and deliver precision radiation treatments for patients with cancer and neurological disorders.

The company’s portfolio includes linear accelerators, stereotactic radiosurgery systems, brachytherapy solutions, treatment-planning and oncology information software, and magnetic resonance-guided radiation therapy technology.